Neuronetics (NASDAQ: STIM) reported Q4 EPS of ($0.41), $0.03 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $17.4 million versus the consensus estimate of $16.94 million.

Fourth Quarter 2019 Highlights

• Fourth quarter 2019 revenue of $17.4 million, an increase of 11% over the fourth quarter of 2018
• Fourth quarter 2019 U.S. treatment session revenue of $11.2 million, an increase of 13% over the fourth quarter of 2018
• Fourth quarter 2019 U.S. NeuroStar® Advanced Therapy revenue of $5.4 million, an increase of 14% over the fourth quarter of 2018
• Active installed base was 1,085, as of December 31, 2019, an increase of 20% over the prior year period

“Our performance in the fourth quarter was in line with our expectations, and we were very pleased to see the continued rapid expansion of our active installed base, which we have sustainably grown by approximately 20% year over year over the last seven quarters,” said Chris Thatcher, President and Chief Executive Officer of Neuronetics. “The trend of increased penetration into ‘TMS only providers’ continued during the quarter, which we view as a positive as these are businesses that treat high volumes of patients across multiple treatment locations and have consistently selected NeuroStar Advanced Therapy as their TMS solution of choice for the treatment of Major Depressive Disorder.”

For earnings history and earnings-related data on Neuronetics (STIM) click here.